Oppenheimer & Co’s Nuvectis Pharma NVCT Stock Holding History

Oppenheimer & Co’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.82M	Buy	86,291 +12,725	+17%	+$268K	0.02%	660
2026 Q2	$1.35M	Hold	73,566	–	–	0.01%	801
2026 Q1	$569K	Hold	73,566	–	–	0.01%	1138
2025 Q4	$555K	Buy	73,566 +4,500	+7%	+$29.3K	0.01%	1035
2025 Q3	$416K	Hold	69,066	–	–	0.01%	1250
2025 Q2	$516K	Buy	69,066 +28,066	+68%	+$255K	0.01%	1135
2025 Q1	$401K	Buy	41,000 +16,000	+64%	+$115K	0.01%	1154
2024 Q4	$135K	Buy	+25,000	New	+$157K	﹤0.01%	1492

Other funds holding NVCT

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Oppenheimer & Co's NVCT Position: Q3 2026 in Review

Oppenheimer & Co increased its Nuvectis Pharma (NVCT) stake by 17% in Q3 2026, buying an estimated $268K and bringing the position to 86,291 shares worth $1.82M. The position accounts for 0.02% of the portfolio, ranked #660.

Oppenheimer & Co first reported a position in NVCT in Q4 2024 and has held it in 8 quarters since. 15 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

Oppenheimer & Co held 86,291 shares of Nuvectis Pharma worth $1.82M as of Q3 2026.
Oppenheimer & Co bought 12,725 Nuvectis Pharma shares in Q3 2026, an estimated $268K.
Nuvectis Pharma made up 0.02% of Oppenheimer & Co's portfolio in Q3 2026, its #660 holding.
Oppenheimer & Co first reported a position in Nuvectis Pharma in Q4 2024 and has held it in 8 quarters since.
15 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.